"Whether the modest trend in biochemical failure differences will sustain and translate into prostate cancer-specific or ...

A randomized trial compared short-term androgen deprivation with high-dose radiotherapy (STADT-RT) and high-dose radiation therapy alone in localized prostate cancer.

MEN with aggressive prostate cancer could benefit from a new drug combination that slows cancer growth, scientists say.

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

An international study reports that the combination of two drugs could significantly retard the development of a dangerous ...

Patients with metastatic hormone-sensitive prostate cancer had similar overall survival no matter whether metformin was added to standard of care in a randomized trial. Metformin use was associated ...

The investigators hypothesized that the use of proton therapy for extended lymph node irradiation of the pelvic and ...

Prostate cancer diagnoses have risen by almost a tenth in a year. Some 58,218 men in England were diagnosed with the disease last year – up by almost 5,000 on the year before – official data has ...

Men whose fathers diagnosed with prostate cancer at an early age faced a fourfold higher risk for early-onset prostate cancer, with a particularly elevated risk for high Gleason score disease. Also, ...

Men with prostate cancer can safely exercise, benefiting from reduced treatment side effects, improved mental health, and ...

This early stage is often detected through routine screenings, such as a prostate-specific antigen (PSA) blood test and a digital rectal exam (DRE), before any symptoms arise. Because the disease is ...